-
1 day ago | 
ascopost.com | Matthew Stenger
In a Japanese phase II study (NO LIMIT, WJOG13320G) reported in the Journal of Clinical Oncology, Kawakami et al evaluated whether first-line nivolumab plus low-dose ipilimumab showed activity in patients with microsatellite instability–high (MSI-H) advanced gastric/esophagogastric junction cancer.
-
1 week ago | 
ascopost.com | Matthew Stenger
In a phase II trial (RAVENS) reported in the Journal of Clinical Oncology, Wang et al attempted to determine whether the addition of the bone metastasis–targeting agent radium-223 to stereotactic ablative radiotherapy improved progression-free survival as metastasis-directed therapy in patients with oligometastatic castration-sensitive prostate cancer and bone metastasis.
-
1 week ago | 
ascopost.com | Matthew Stenger
In a French phase III trial (NEOPAN) reported in the Journal of Clinical Oncology, Ducreux et al evaluated whether FOLFIRINOX (fluorouracil, oxaliplatin, and irinotecan) significantly improved progression-free survival vs gemcitabine in patients with locally advanced pancreatic carcinoma not suitable for surgery.
-
1 week ago | 
ascopost.com | Matthew Stenger
In a study reported in JAMA Oncology, Heyward et al examined the harm-benefit balance of immune checkpoint inhibitor use across lines of treatment in non–small cell lung cancer (NSCLC). Study DetailsThe retrospective cohort study, conducted in 2024, involved 2013 to 2019 Surveillance, Epidemiology, and End Results–Medicare data on patents aged 66 years or older with NSCLC who were exposed to immune checkpoint inhibitor plus chemotherapy or immune checkpoint inhibitor alone.
-
1 week ago | 
ascopost.com | Matthew Stenger
In a phase III trial (CheckMate 9DW) reported in The Lancet, Yau et al evaluated whether first-line nivolumab plus ipilimumab improved overall survival vs investigator's choice of lenvatinib or sorafenib in patients with unresectable hepatocellular carcinoma.
-
1 week ago | 
ascopost.com | Matthew Stenger
In a single-center phase I trial reported in The New England Journal of Medicine, Svoboda et al assessed the safety, feasibility, and preliminary efficacy of an enhanced chimeric antigen receptor (CAR) T-cell therapy (huCART19-IL18) in patients with relapsed or refractory lymphoma after previous anti-CD19 CAR T-cell therapy. As stated by the investigators, “…CAR T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission.
-
1 week ago | 
ascopost.com | Matthew Stenger
In a Belgian phase III trial (ROBOMET) reported in the Journal of Clinical Oncology, Mercier et al attempted to determine whether dose-escalated, single-fraction stereotactic body radiotherapy was associated with statistically significant benefit vs conventional, single-fraction, 3D conformal radiotherapy in the 1-month rate of complete pain response in patients with painful bone metastases.
-
1 week ago | 
ascopost.com | Matthew Stenger
In a Danish Breast Cancer Group nationwide prospective cohort study reported in The Lancet Oncology, Jensen et al attempted to develop a prognostic standard mortality rate index to predict excess mortality based on risk-adapted adjuvant therapy in postmenopausal patients with early-stage breast cancer.
-
2 weeks ago | 
ascopost.com | Matthew Stenger
In a phase II trial reported in the Journal of Clinical Oncology, Chen et al attempted to determine whether there is a benefit to adding tocilizumab to nab-paclitaxel and gemcitabine in the first-line treatment of patients with advanced pancreatic cancer.
-
2 weeks ago | 
ascopost.com | Matthew Stenger
In an international cohort study reported in The Lancet Oncology, Blondeaux et al evaluated whether both risk-reducing mastectomy and risk-reducing salpingo-oophorectomy were associated with improved survival among women aged 40 or younger who have invasive breast cancer with germline BRCA1/2 pathogenic variants. Study DetailsThe study involved patients from the BRCA BCY Collaboration. The collaboration is a hospital-based, retrospective cohort study, conducted at 109 sites in five continents.
